Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:27 AM
Ignite Modification Date:
2025-12-25 @ 3:27 AM
NCT ID:
NCT00372905
Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed follicular lymphoma
* CD20+ at time of diagnosis or subsequently
* More than 4 weeks since prior rituximab
* More than 3 weeks since prior anticancer therapy (6 weeks for nitrosourea or mitomycin C)
* More than 4 weeks since prior major surgery
* More than 2 weeks since prior investigational drugs
Exclusion Criteria:
* AIDS-related lymphoma
* History or evidence of CNS involvement
* Pregnant or nursing
* known HIV positivity
* serious medical or psychiatric illness that would preclude study participation
* myocardial infarction within the past 6 months
* congestive heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia or active conduction system abnormalities
* known hypersensitivity to rituximab, bortezomib, boron, or mannitol
* prior autologous or allogeneic stem cell transplantation
* prior radioimmunoconjugate therapy or prior exposure to murine antibodies
* prior external-beam irradiation to \> 25% of active bone marrow
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00372905
Study Brief:
Protocol Section:
NCT00372905